FDA Panel recommends Darvocet Recall

A panel of outside advisors to the FDA have recommended they withdraw their approval for the painkiller Darvon and Darvocet. The panel found that the minimal pain relief benefits provided by the drugs do not outweigh the substantial risk of overdose, suicide and other known side effects.

Although the FDA is not required to follow the advice of their advisory panel, they usually follow their panel’s recommendation.

According to an FDA analysis, more than 3,000 serious reports of Darvon and Darvocet problems were identified, with most involving suicides, addiction and overdoses.

The advisory panel voted 14 to 12 to recommend a recall.